DNA polymerase alpha 1, catalytic subunitGenealiases: NSX · PDR · POLA · VEODS · p180
Q-omics provides the consensus-scored POLA1 profile across patient tissues and cancer cell-line models. POLA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, POLA1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, POLA1 protein abundance shows 23,065 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, HNSC, and GBM as cancer lineages where POLA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLA1 survival associations across molecular data types. POLA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLA1 RNA expression–survival associations across cancer types. High POLA1 expression shows unfavorable associations in UVM, MESO, KIRP and LIHC, but favorable associations in KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for POLA1 RNA expression.
This table summarizes POLA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POLA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLA1 shows higher tumor expression in HNSC, COAD, LIHC, STAD, BLCA and LUSC. The HNSC box plot shows higher POLA1 RNA expression in tumor versus normal tissue (log2 FC = +0.655, t-test p < 0.001).
This table shows molecular features associated with POLA1 in patient tissues and cancer cell lines. In patient samples, POLA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, POLA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
